Form 4: ONCY Director Boosts Stake with $10,300 Share Purchase

Oncolytics Biotech Director James T. Parsons acquired 10,000 common shares at $1.03 each, increasing his direct beneficial ownership to 41,849 shares.

Summary

• James T. Parsons, a Director of Oncolytics Biotech Inc. (ONCY), purchased 10,000 common shares.
• The transaction occurred on March 11, 2026, at a price of $1.03 per share.
• Following this acquisition, Mr. Parsons directly beneficially owns a total of 41,849 common shares.
• The total value of the shares acquired in this transaction is $10,300.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake typically indicates confidence in the company's future performance and intrinsic value.

Positives

• A Director increasing their stake in the company signals confidence in its future prospects and valuation.
• The purchase was made at a specific price of $1.03 per share, indicating a belief in the company's value at or above this level.

Industry Context

StockSavvy.ai notes that insider purchases, such as this director's acquisition, are often interpreted by the market as a positive signal, indicating that those with intimate knowledge of the company believe its stock is undervalued or has strong future potential. This activity can sometimes precede positive company developments or improved financial performance.

Related Party Transactions

• Director James T. Parsons, a related party, acquired 10,000 common shares from the issuer at $1.03 per share.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a positive signal of management confidence in the company's future performance, potentially influencing investor sentiment.

Key Dates

Recommendation

The director's purchase of additional shares signals confidence in the company's future prospects, which can be a positive indicator for investors. While a single transaction, it suggests an insider believes the stock is a good value at the current price.

Keywords

ONCY, Oncolytics Biotech, Insider Trading, Director Purchase, Form 4, Common Shares, Stock Acquisition